Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Current Assets: 2017-2025

Historic Current Assets for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $857.0 million.

  • Arcus Biosciences' Current Assets fell 23.96% to $857.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $857.0 million, marking a year-over-year decrease of 23.96%. This contributed to the annual value of $1.0 billion for FY2024, which is 22.26% up from last year.
  • Latest data reveals that Arcus Biosciences reported Current Assets of $857.0 million as of Q3 2025, which was down 9.41% from $946.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Current Assets peaked at $1.3 billion during Q1 2022, and registered a low of $545.3 million during Q3 2021.
  • Moreover, its 3-year median value for Current Assets was $1.0 billion (2023), whereas its average is $979.7 million.
  • The largest annual percentage gain for Arcus Biosciences' Current Assets in the last 5 years was 406.49% (2021), contrasted with its biggest fall of 31.60% (2021).
  • Quarterly analysis of 5 years shows Arcus Biosciences' Current Assets stood at $1.3 billion in 2021, then fell by 15.45% to $1.1 billion in 2022, then decreased by 22.12% to $831.0 million in 2023, then rose by 22.26% to $1.0 billion in 2024, then declined by 23.96% to $857.0 million in 2025.
  • Its Current Assets was $857.0 million in Q3 2025, compared to $946.0 million in Q2 2025 and $1.0 billion in Q1 2025.